Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida. Show more

Location: 601 Brickell Key Drive, Miami, FL, 33131, United States | Website: https://www.smmttx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

16.56B

52 Wk Range

$15.55 - $36.91

Previous Close

$22.29

Open

$22.48

Volume

1,660,096

Day Range

$22.39 - $23.58

Enterprise Value

15.21B

Cash

297.9M

Avg Qtr Burn

-51.72M

Insider Ownership

84.35%

Institutional Own.

13.55%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ivonescimab (SMT112) Details 1L Non-small cell lung carcinoma	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC (2L+ EGFRm NSCLC)	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab Details 1L PD-L1 positive Non-small cell lung carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab Details PD-L1 positive NSCLC	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab (SMT112) +Chemotherapy Details Biliary Tract Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ridinilazole Details Intestinal infection, Bacterial infection	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.